Replimune Group (Replimune Group) 3-Year Book Growth Rate : -17.10% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Replimune Group 3-Year Book Growth Rate?

Replimune Group's Book Value per Share for the quarter that ended in Mar. 2024 was $6.10.

During the past 12 months, Replimune Group's average Book Value per Share Growth Rate was -37.80% per year. During the past 3 years, the average Book Value per Share Growth Rate was -17.10% per year. During the past 5 years, the average Book Value per Share Growth Rate was 10.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 8 years, the highest 3-Year average Book Value per Share Growth Rate of Replimune Group was 25.90% per year. The lowest was -17.10% per year. And the median was 25.10% per year.

Competitive Comparison of Replimune Group's 3-Year Book Growth Rate

For the Biotechnology subindustry, Replimune Group's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Replimune Group's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Replimune Group's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Replimune Group's 3-Year Book Growth Rate falls into.

Replimune Group 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Replimune Group (NAS:REPL) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Replimune Group 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Replimune Group's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Replimune Group (Replimune Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Replimune Group Inc (NAS:REPL) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

7R8:Germany

Address

500 Unicorn Park Drive, Suite 303, Woburn, MA, USA, 01801

Website

https://www.replimune.com

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Executives

Christopher Sarchi	officer: Chief Commercial Officer	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Konstantinos Xynos	officer: Chief Medical Officer	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Emily Luisa Hill	officer: Chief Financial Officer	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Pamela Esposito	officer: Chief Business Officer	C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Sushil Patel	officer: Chief Commercial Officer	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK, THIRD FLOOR, WOBURN MA 01801
Tanya Lewis	director	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459
Veleka Peeples-dyer	director	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Andrew Schwendenman	officer: Chief Accounting Officer	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Philip Astley-sparke	director, 10 percent owner, officer: Executive Chairman	C/O BIOVEX GROUP, INC., 34 COMMERCE WAY, WOBURN MA 10801
Robert Coffin	director, 10 percent owner, officer: President and C.E.O.	C/O BIOVEX GROUP, INC., 34 COMMERCE WAY, WOBURN MA 10801
Love Colin	10 percent owner, officer: Chief Operating Officer	C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 10801
Jean M. Franchi	officer: Chief Financial Officer	C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Omega Fund Iv Gp, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Christy J. Oliger	director	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Jason P Rhodes	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139